.png "Janet Woodcock"){kind=small}
Robert Califf
Search results
Janet Woodcock (born August 29, 1948) is an American physician serving as Principal Deputy Commissioner of Food and Drugs, having previously served as Acting Commissioner of the U.S. Food and Drug Administration (FDA).
- Roger Miller
- Robert Califf
Feb 17, 2022 · Learn about Dr. Janet Woodcock, the FDA’s Principal Deputy Commissioner who works with the Commissioner of Food and Drugs to develop and implement key public health initiatives and oversee the agency’s day-to-day functions. She is a leading expert in drug development, safety, and innovation, and has been honored with many awards for her achievements.
- Principal Deputy Commissioner
- Office of The Commissioner
Nov 17, 2023 · WOODCOCK SET TO RETIRE — Longtime FDA regulator Janet Woodcock, who has worked at the agency since 1986, plans to retire in early 2024, FDA Commissioner Robert Califf told agency staff...
Nov 16, 2023 · WASHINGTON, Nov 16 (Reuters) - U.S. Food and Drug Administration (FDA) Principal Deputy Commissioner Dr. Janet Woodcock, who led the regulator during the height of the COVID-19 pandemic as...
Jan 29, 2024 · Dr. Janet Woodcock speaks to Focus. (Source: Ferdous Al-Faruque) This Wednesday will be Dr. Janet Woodcock’s last day at the US Food and Drug Administration (FDA), capping a remarkable 38-year career at the agency. She’s been called one of the most powerful and influential drug regulators worldwide. Last Thursday, Focus sat down with ...
Nov 16, 2023 · Janet Woodcock, the deputy commissioner of the Food and Drug Administration, confirmed she will retired next year after nearly four decades at the agency. Brendan Smialowski/Bloomberg News. Nov. 16, 2023, 2:19 PM PST. FDA’s Woodcock to Retire After Career Marked by Controversy (3) Nyah Phengsitthy. Reporter. Jeannie Baumann. Senior Reporter.
Nov 17, 2023 · Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.
